Alexis E Whitton1, Poornima Kumar2, Michael T Treadway3, Ashleigh V Rutherford2, Manon L Ironside2, Dan Foti4, Garrett Fitzmaurice2, Fei Du2, Diego A Pizzagalli5. 1. Center for Depression, Anxiety and Stress Research, McLean Hospital, Belmont, Massachusetts; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts; Black Dog Institute, University of New South Wales, Randwick, New South Wales, Australia. 2. Center for Depression, Anxiety and Stress Research, McLean Hospital, Belmont, Massachusetts; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts. 3. Department of Psychology, Emory University, Atlanta, Georgia. 4. Department of Psychological Sciences, Purdue University, West Lafayette, Indiana. 5. Center for Depression, Anxiety and Stress Research, McLean Hospital, Belmont, Massachusetts; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts. Electronic address: dap@mclean.harvard.edu.
Abstract
BACKGROUND: The National Institute of Mental Health Research Domain Criteria (RDoC) initiative aims to establish a neurobiologically valid framework for classifying mental illness. Here, we examined whether the RDoC construct of reward learning and three aspects of its underlying neurocircuitry predicted symptom trajectories in individuals with mood pathology. METHODS: Aligning with the RDoC approach, we recruited individuals (n = 80 with mood disorders [58 unipolar and 22 bipolar] and n = 32 control subjects; 63.4% female) based on their performance on a laboratory-based reward learning task rather than clinical diagnosis. We then assessed 1) anterior cingulate cortex prediction errors using electroencephalography, 2) striatal reward prediction errors using functional magnetic resonance imaging, and 3) medial prefrontal cortex glutamatergic function (mPFC Gln/Glu) using 1H magnetic resonance spectroscopy. Severity of anhedonia, (hypo)mania, and impulsivity were measured at baseline, 3 months, and 6 months. RESULTS: Greater homogeneity in aspects of brain function (mPFC Gln/Glu) was observed when individuals were classified according to reward learning ability rather than diagnosis. Furthermore, mPFC Gln/Glu levels predicted more severe (hypo)manic symptoms cross-sectionally, predicted worsening (hypo)manic symptoms longitudinally, and explained greater variance in future (hypo)manic symptoms than diagnostic information. However, rather than being transdiagnostic, this effect was specific to individuals with bipolar disorder. Prediction error indices were unrelated to symptom severity. CONCLUSIONS: Although findings are preliminary and require replication, they suggest that heightened mPFC Gln/Glu warrants further consideration as a predictor of future (hypo)mania. Importantly, this work highlights the value of an RDoC approach that works in tandem with, rather than independent of, traditional diagnostic frameworks.
BACKGROUND: The National Institute of Mental Health Research Domain Criteria (RDoC) initiative aims to establish a neurobiologically valid framework for classifying mental illness. Here, we examined whether the RDoC construct of reward learning and three aspects of its underlying neurocircuitry predicted symptom trajectories in individuals with mood pathology. METHODS: Aligning with the RDoC approach, we recruited individuals (n = 80 with mood disorders [58 unipolar and 22 bipolar] and n = 32 control subjects; 63.4% female) based on their performance on a laboratory-based reward learning task rather than clinical diagnosis. We then assessed 1) anterior cingulate cortex prediction errors using electroencephalography, 2) striatal reward prediction errors using functional magnetic resonance imaging, and 3) medial prefrontal cortex glutamatergic function (mPFC Gln/Glu) using 1H magnetic resonance spectroscopy. Severity of anhedonia, (hypo)mania, and impulsivity were measured at baseline, 3 months, and 6 months. RESULTS: Greater homogeneity in aspects of brain function (mPFC Gln/Glu) was observed when individuals were classified according to reward learning ability rather than diagnosis. Furthermore, mPFC Gln/Glu levels predicted more severe (hypo)manic symptoms cross-sectionally, predicted worsening (hypo)manic symptoms longitudinally, and explained greater variance in future (hypo)manic symptoms than diagnostic information. However, rather than being transdiagnostic, this effect was specific to individuals with bipolar disorder. Prediction error indices were unrelated to symptom severity. CONCLUSIONS: Although findings are preliminary and require replication, they suggest that heightened mPFC Gln/Glu warrants further consideration as a predictor of future (hypo)mania. Importantly, this work highlights the value of an RDoC approach that works in tandem with, rather than independent of, traditional diagnostic frameworks.
Authors: Diane L Santesso; A Eden Evins; Michael J Frank; Erika C Schetter; Ryan Bogdan; Diego A Pizzagalli Journal: Hum Brain Mapp Date: 2009-07 Impact factor: 5.038
Authors: Kristen L Eckstrand; Erika E Forbes; Michele A Bertocci; Henry W Chase; Tsafrir Greenberg; Jeanette Lockovich; Ricki Stiffler; Haris A Aslam; Simona Graur; Genna Bebko; Mary L Phillips Journal: JAMA Psychiatry Date: 2019-09-01 Impact factor: 21.596
Authors: Diane L Santesso; Daniel G Dillon; Jeffrey L Birk; Avram J Holmes; Elena Goetz; Ryan Bogdan; Diego A Pizzagalli Journal: Neuroimage Date: 2008-07-02 Impact factor: 6.556
Authors: Jonathan Chabert; Etienne Allauze; Bruno Pereira; Carine Chassain; Ingrid De Chazeron; Jean-Yves Rotgé; Philippe Fossati; Pierre-Michel Llorca; Ludovic Samalin Journal: Int J Mol Sci Date: 2022-08-11 Impact factor: 6.208